<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Case 1 was a 58-year-old woman diagnosed with unresectable <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> from advanced <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We performed laparoscopic low anterior resection for <z:e sem="disease" ids="C0751498" disease_type="Neoplastic Process" abbrv="">sigmoid cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>As the first-line treatment, FOLFOX+bevacizumab(BV)was applied for 16 courses </plain></SENT>
<SENT sid="3" pm="."><plain>The second-line treatment, FOLFIRI plus BV, was applied for four courses </plain></SENT>
<SENT sid="4" pm="."><plain>However, the disease progressed with worsening <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The sequencing of K-<z:mp ids='MP_0011356'>RAS</z:mp> genes from the biopsy specimens of sigmoid <z:hpo ids='HP_0003003'>colon cancer</z:hpo> revealed an expression of a <z:mp ids='MP_0002169'>wild-type</z:mp> K-<z:mp ids='MP_0011356'>RAS</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>As the third-line treatment, panitumumab was applied </plain></SENT>
<SENT sid="7" pm="."><plain>After 8 courses of this chemotherapy regimen, a significant reduction in the size of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> was observed </plain></SENT>
<SENT sid="8" pm="."><plain>Case 2 was an 81-year-old man diagnosed with unresectable <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> from advanced <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>We obliged the patient by performing laparoscopic rectal resection </plain></SENT>
<SENT sid="10" pm="."><plain>As the first-line treatment, XELOX plus BV was applied for 10 courses </plain></SENT>
<SENT sid="11" pm="."><plain>As the second-line treatment, IRIS was applied for 6 courses </plain></SENT>
<SENT sid="12" pm="."><plain>However, this failed to prevent him from having a progressive disease </plain></SENT>
<SENT sid="13" pm="."><plain>As the third-line treatment, panitumumab was applied for 2 courses, and a significant reduction in the size of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> was observed </plain></SENT>
<SENT sid="14" pm="."><plain>Our findings suggested that panitumumab has great potential for effective treatment of patients with unresectable <z:e sem="disease" ids="C0677950" disease_type="Neoplastic Process" abbrv="">stageIV colorectal cancer</z:e> </plain></SENT>
</text></document>